EVE Evolva Holding SA

Evolva Business Update

Evolva (SIX: EVE) today provides a quarterly business update, showing a strong underlying dynamic in building the business. The key items are:

Product sales

  • Product sales continued a solid growth trend, although sales have shown seasonal effects with summer months being significantly lower compared to the rest of the year.
  • For the full year 2018, we expect product sales to grow at a high double digit percentage rate.
  • The sales development pipeline continues to gain momentum, supporting further growth in 2019.
  • The filing for registration of nootkatone for pest control applications remains on track at the US Environmental Protection Agency.

Other sources of revenue

  • As Cargill has commercially launched EverSweet™, first royalty income from EverSweet™ product sales are expected, albeit modest, in the fourth quarter of 2018.
  • On November 8, 2018, Cargill and Royal DSM announced a new venture which will combine both companies’ technologies for producing steviol glycoside products made through fermentation and will market its products under one brand name, EverSweet™.
  • Evolva’s royalty rights on EverSweet™ and the existing agreement between Cargill and Evolva remain unchanged.
  • Revenues from non-core R&D partner projects continue to decline in 2018, in line with our strategy to focus on value adding, commercially attractive products.

Costs and restructuring activities

  • Combined efforts in R&D and manufacturing have resulted in a focused program to significantly lower manufacturing costs over the coming years.
  • A full supply chain and network of service providers is being put in place to enable to ramp up volumes.
  • The restructuring activities to transform Evolva, started in August 2017, will be completed by November of this year. As a result expenses in the coming years will be lower than earlier communicated levels.

- ends -

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and fermentation. We develop, make and sell ingredients that provide significant health, wellness and nutrition benefits to people in their daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. For more information see .

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

EN
09/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evolva Holding SA

 PRESS RELEASE

Shareholders of Evolva Holding SA in liquidation approve BoD proposals...

Evolva Holding SA / Key word(s): AGMEGM Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected 12.04.2024 / 19:10 CET/CEST PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR   Shareholders of Evolva Holding SA in liquidation approve proposals put forward by the Board of Directors at Annual General Meeting; of the three agenda items put forward by Nice & Green, revocation of the liquidation and the delisting were also approved whereas introduc...

 PRESS RELEASE

Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG...

Evolva Holding SA / Key word(s): Takeover Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 28.12.2023 / 17:45 CET/CEST PRESS RELEASE   Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 Reinach, Switzerland, 28 December 2023 — Following the approval on 21 December 2023 by the shareholders of Evolva Holding AG (SIX: EVE) of the sale of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., the parties have successfully closed the transaction on 28 December 2023. Evolva Holding S...

 PRESS RELEASE

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss sub...

Evolva Holding SA / Key word(s): AGMEGM Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting 21.12.2023 / 17:45 CET/CEST PRESS RELEASE   Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting Reinach, 21 December 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved all the proposals put forward by the Board of Directors at today’s extraordinary general meeting (EGM). The sharehol...

 PRESS RELEASE

Evolva and Breko broaden partnership by signing agreement for the excl...

Evolva Holding SA / Key word(s): Agreement Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam 14.11.2023 / 07:00 CET/CEST PRESS RELEASE   Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTMResveratrol in Germany, Austria, Thailand and Vietnam Reinach, 14 November 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and Breko GmbH, Bremen, Germany (“Breko”), a leading supplier of p...

 PRESS RELEASE

Evolva shareholders approve increase of the conditional capital and up...

Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 24.08.2023 / 20:00 CET/CEST PRESS RELEASE   Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 Reinach, 24 August 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved the proposals put forward by the Board of Direct...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch